Table 3. Hazard ratio (95% CI) of mortality by sleep measures

<table>
<thead>
<tr>
<th></th>
<th>All cause (628 deaths)</th>
<th>CVD (217 deaths)</th>
<th>Cancer (171 deaths)</th>
<th>Non-cancer Non-CVD (240 deaths)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AHI ≥30 vs. &lt;30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td>1.06 (0.86-1.29)</td>
<td><strong>1.38 (1.00-1.90)</strong></td>
<td>0.89 (0.59-1.34)</td>
<td>0.90 (0.63-1.27)</td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td>1.03 (0.84-1.27)</td>
<td>1.35 (0.98-1.88)</td>
<td>0.88 (0.58-1.33)</td>
<td>0.86 (0.60-1.24)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.03 (0.84-1.26)</td>
<td>1.33 (0.97-1.84)</td>
<td>0.88 (0.59-1.33)</td>
<td>0.87 (0.61-1.24)</td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>1.03 (0.84-1.27)</td>
<td>1.34 (0.97-1.85)</td>
<td>0.87 (0.58-1.32)</td>
<td>0.87 (0.61-1.26)</td>
</tr>
<tr>
<td><strong>≥10% vs. &lt;10% TST SaO₂&lt;90%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td><strong>1.28 (1.02-1.61)</strong></td>
<td>1.24 (0.85-1.80)</td>
<td>1.30 (0.84-1.99)</td>
<td>1.32 (0.91-1.92)</td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td>1.13 (0.90-1.43)</td>
<td>1.12 (0.77-1.64)</td>
<td>1.29 (0.83-2.00)</td>
<td>1.09 (0.74-1.60)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.17 (0.93-1.46)</td>
<td>1.08 (0.74-1.58)</td>
<td>1.27 (0.83-1.96)</td>
<td>1.17 (0.80-1.70)</td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>1.07 (0.85-1.35)</td>
<td>1.02 (0.69-1.49)</td>
<td>1.27 (0.82-1.98)</td>
<td>1.00 (0.68-1.47)</td>
</tr>
<tr>
<td><strong>≥1% vs. &lt;1% TST SaO₂&lt;80%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td><strong>1.58 (1.15-2.20)</strong></td>
<td>1.54 (0.90-2.65)</td>
<td><strong>2.46 (1.45-4.17)</strong></td>
<td>0.99 (0.50-1.94)</td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td><strong>1.54 (1.09-2.16)</strong></td>
<td>1.53 (0.88-2.68)</td>
<td><strong>2.30 (1.35-3.92)</strong></td>
<td>0.81 (0.37-1.78)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.54 (1.11-2.14)</td>
<td>1.48 (0.86-2.55)</td>
<td><strong>2.45 (1.44-4.14)</strong></td>
<td>0.94 (0.48-1.86)</td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>1.57 (1.11-2.22)</td>
<td>1.62 (0.93-2.84)</td>
<td><strong>2.31 (1.36-3.94)</strong></td>
<td>0.82 (0.38-1.81)</td>
</tr>
<tr>
<td><strong>TST &lt;5 vs. 5-8</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td><strong>1.28 (1.02-1.62)</strong></td>
<td>1.25 (0.85-1.84)</td>
<td>0.98 (0.61-1.58)</td>
<td><strong>1.56 (1.09-2.24)</strong></td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td>1.17 (0.92-1.48)</td>
<td>1.19 (0.80-1.77)</td>
<td>0.94 (0.58-1.53)</td>
<td>1.35 (0.92-1.97)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.20 (0.95-1.51)</td>
<td>1.15 (0.78-1.69)</td>
<td>0.97 (0.60-1.56)</td>
<td><strong>1.45 (1.01-2.08)</strong></td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>1.12 (0.89-1.42)</td>
<td>1.12 (0.76-1.67)</td>
<td>0.93 (0.58-1.52)</td>
<td>1.28 (0.87-1.88)</td>
</tr>
<tr>
<td><strong>TST &gt;8 vs. 5-8</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td>1.02 (0.76-1.37)</td>
<td>0.93 (0.55-1.55)</td>
<td>0.59 (0.29-1.20)</td>
<td>1.46 (0.96-2.21)</td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td>0.94 (0.69-1.27)</td>
<td>0.92 (0.55-1.55)</td>
<td>0.57 (0.27-1.17)</td>
<td>1.29 (0.83-2.00)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.03 (0.77-1.38)</td>
<td>0.94 (0.56-1.57)</td>
<td>0.59 (0.29-1.20)</td>
<td>1.47 (0.97-2.22)</td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>0.83 (0.71-1.31)</td>
<td>0.95 (0.56-1.61)</td>
<td>0.57 (0.28-1.18)</td>
<td>1.32 (0.85-2.05)</td>
</tr>
<tr>
<td><strong>Sleep latency ≥60 vs. &lt;60 min</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1: Crude model</td>
<td>1.25 (0.99-1.58)</td>
<td>1.24 (0.84-1.84)</td>
<td>1.23 (0.78-1.93)</td>
<td>1.28 (0.88-1.87)</td>
</tr>
<tr>
<td>Model 2a: Model 1 + MV</td>
<td>1.13 (0.89-1.44)</td>
<td>1.14 (0.76-1.71)</td>
<td>1.22 (0.77-1.94)</td>
<td>1.06 (0.71-1.58)</td>
</tr>
<tr>
<td>Model 2b: Model 1 + # high inflammatory markers</td>
<td>1.19 (0.94-1.50)</td>
<td>1.15 (0.78-1.70)</td>
<td>1.22 (0.77-1.92)</td>
<td>1.20 (0.82-1.75)</td>
</tr>
<tr>
<td>Model 3: Model 1 + MV* + # high inflammatory markers</td>
<td>1.12 (0.88-1.42)</td>
<td>1.13 (0.75-1.69)</td>
<td>1.25 (0.79-1.98)</td>
<td>1.04 (0.70-1.56)</td>
</tr>
</tbody>
</table>